- Tytuł:
- Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
- Autorzy:
- Źródło:
- Clinical and translational science [Clin Transl Sci] 2021 Jul; Vol. 14 (4), pp. 1535-1542. Date of Electronic Publication: 2021 Apr 09.
- Typ publikacji:
- Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
- MeSH Terms:
-
ATP Binding Cassette
Transporter , Subfamily G, Member 2/*antagonists & inhibitors
Drug Approval/*statistics & numerical dataLiver -Specific Organic Anion Transporter 1 /*antagonists & inhibitors
Neoplasm Proteins/*antagonists & inhibitorsOrganic Anion Transporters, Sodium-Independent /*antagonists & inhibitors
Tolvaptan/*pharmacology
ATP Binding CassetteTransporter , Subfamily G, Member 2/metabolism ; Adult ; Clinical Trials as Topic/standards ; Cross-Over Studies ; Drug Interactions ; Female ; Furosemide/pharmacology ; Furosemide/therapeutic use ; Guidelines as Topic ; HEK293 Cells ; Half-Life ; Humans ;Liver -Specific Organic Anion Transporter 1 /metabolism ; Male ; Neoplasm Proteins/metabolism ;Organic Anion Transporters, Sodium-Independent /metabolism ; Rosuvastatin Calcium/pharmacology ; Rosuvastatin Calcium/therapeutic use ; Tolvaptan/metabolism ; Tolvaptan/therapeutic use ; United States ; United States Food and Drug Administration/standards ; Young Adult
Czasopismo naukowe